These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14871645)

  • 1. Peptide-based immunotherapy of systemic lupus erythematosus.
    Monneaux F; Muller S
    Autoimmun Rev; 2004 Jan; 3(1):16-24. PubMed ID: 14871645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-nucleosome antibodies and T-cell response in systemic lupus erythematosus.
    Fournel S; Muller S
    Ann Med Interne (Paris); 2002 Dec; 153(8):513-9. PubMed ID: 12610425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells.
    Grimaldi CM
    Curr Opin Rheumatol; 2006 Sep; 18(5):456-61. PubMed ID: 16896282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus.
    Hahn BH; Singh RR; Wong WK; Tsao BP; Bulpitt K; Ebling FM
    Arthritis Rheum; 2001 Feb; 44(2):432-41. PubMed ID: 11229475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells.
    Suen JL; Chuang YH; Tsai BY; Yau PM; Chiang BL
    Arthritis Rheum; 2004 Oct; 50(10):3250-9. PubMed ID: 15476240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients.
    Hahn BH; Anderson M; Le E; La Cava A
    Arthritis Rheum; 2008 Aug; 58(8):2488-97. PubMed ID: 18668553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-establishing tolerance to DNA in humanized and murine models of SLE.
    Nikolova K; Mihaylova N; Voynova E; Kerekov N; Gesheva V; Prechl J; Nikolova M; Tchorbanov A
    Autoimmun Rev; 2010 May; 9(7):499-502. PubMed ID: 20149897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis.
    Rottman JB; Willis CR
    Vet Pathol; 2010 Jul; 47(4):664-76. PubMed ID: 20448279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of autoreactive B cells in humanized SCID mouse model of SLE.
    Kerekov NS; Mihaylova NM; Grozdev I; Todorov TA; Nikolova M; Baleva M; Nikolova M; Prechl J; Erdei A; Tchorbanov AI
    Eur J Immunol; 2011 Nov; 41(11):3301-11. PubMed ID: 21830207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract.
    Ofosu-Appiah W; Sfeir G; Viti D; Burashnikova E
    J Autoimmun; 1999 Dec; 13(4):405-14. PubMed ID: 10585756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of biologicals for the therapy of lupus erythematosus.
    Neumann D; Tschernig T; Boraschi D
    Expert Rev Vaccines; 2007 Dec; 6(6):1001-11. PubMed ID: 18034656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
    Mozes E; Sharabi A
    Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell-directed therapies in systemic lupus erythematosus.
    Tieng AT; Peeva E
    Semin Arthritis Rheum; 2008 Dec; 38(3):218-27. PubMed ID: 18206214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
    Gabriel L; Morley BJ; Rogers NJ
    Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?
    Dolff S; Abdulahad WH; Bijl M; Kallenberg CG
    Lupus; 2009 Jun; 18(7):575-80. PubMed ID: 19433456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of lupus therapy modulating autoantigen recognition.
    Okamoto A; Fujio K; Yamamoto K
    Lupus; 2010 Oct; 19(12):1474-81. PubMed ID: 20947560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cells in lupus.
    Kang HK; Datta SK
    Int Rev Immunol; 2006; 25(1-2):5-25. PubMed ID: 16531276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble MHC class II-driven therapy for a systemic lupus erythematosus murine experimental in vitro and in vivo model.
    Bakela K; Dimakopoulou M; Batsou P; Manidakis N; Athanassakis I
    Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29412476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies.
    Mahler M; Fritzler MJ; Blüthner M
    Arthritis Res Ther; 2005; 7(1):R19-29. PubMed ID: 15642139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.